Rate of hypoglycemia in patients with type 2 diabetes receiving metformin plus saxagliptin versus metformin plus sulfonylurea: A retrospective observational cohort study using administrative claims data

Expert Review of Endocrinology and Metabolism

Volumn 9, Issue 2, 2014, Pages 183-191

  Curkendall, Suellen Marie ^a   Zhang, Bin ^b   Lenhart, Gregory ^a   Thomson, Erin ^a   Bell, Kelly F ^b  

^a IBM WATSON HEALTH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Healthcare claims data; Hypoglycemia; Saxagliptin; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; SAXAGLIPTIN; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL PRACTICE; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84896713410     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.2014.870471     Document Type: Article

References (17)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364-1379 (2012).
2. Campbell IW. Sulfonylureas and hypoglycemia. Diabetic Hypoglycemia 2, 3-10 (2009).
3. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 13(Suppl. 1), 1-68 (2007).
4. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A concensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009).
5. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: The Fremantle Diabetes Study. J. Clin. Endocinol. Metab. 95(5), 2240-2247 (2010).
6. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365(21), 2002-2012 (2011).
7. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32(9), 1649-1655 (2009).
8. Go?ke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int. J. Clin. Pract. 64(12), 1619-1631 (2010).
9. Curkendall SM, Zhang B, Oh KS, Williams SA, Pollack MF, Graham JP. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database. J. Clin. Outcomes Manag. 18(10), 455-462 (2011).
10. Bonafede MM, Kalsekar A, Pawaskar M et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: A retrospective database analysis. BMC Endocr. Disord. 11, 3 (2011).
11. Lee LJ, Anderson J, Foster SA, Lenox SM, Smith DM, Curkendall SM. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. J. Diabetes Sci. Technol. 4(3), 547-557 (2010).
12. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 34(5), 1164-1170 (2011).
13. Ginde AA, Blanc PG, Lieberman RM, Camargo CA. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr. Disord. 8, 4 (2008).
14. D?Agostino RB. Tutorial in biostatistics propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist. Med. 17, 2265-2281 (1998).
15. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303(14), 1410-1418 (2010).
16. Nauk MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9(2), 194-205 (2007).
17. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 11(2), 157-166 (2009).